|
Name |
Cytoglobosin A
|
Molecular Formula | C32H36N2O5 | |
IUPAC Name* |
(1R,4R,8R,9S,11E,13R,14S,16S,17R,18S)-6,14-dihydroxy-18-(1H-indol-3-ylmethyl)-7,9,16-trimethyl-15-methylidene-19-azatetracyclo[11.7.0.01,17.04,8]icosa-6,11-diene-2,5,20-trione
|
|
SMILES |
C[C@H]1C/C=C/[C@H]2[C@@H](C(=C)[C@H]([C@@H]3[C@@]2(C(=O)C[C@@H]4[C@@H]1C(=C(C4=O)O)C)C(=O)N[C@H]3CC5=CNC6=CC=CC=C65)C)O
|
|
InChI |
InChI=1S/C32H36N2O5/c1-15-8-7-10-22-28(36)17(3)16(2)27-24(12-19-14-33-23-11-6-5-9-20(19)23)34-31(39)32(22,27)25(35)13-21-26(15)18(4)29(37)30(21)38/h5-7,9-11,14-16,21-22,24,26-28,33,36-37H,3,8,12-13H2,1-2,4H3,(H,34,39)/b10-7+/t15-,16+,21+,22-,24-,26-,27-,28+,32+/m0/s1
|
|
InChIKey |
VROGJHMZKMLYET-NKUOSLKNSA-N
|
|
Synonyms |
Cytoglobosin A; CHEBI:68814; CHEMBL1097577; Q27137192; (3S,3aR,4S,6S,6aR,7E,10S,10aR,13aR,15aR)-6,12-dihydroxy-3-(1H-indol-3-ylmethyl)-4,10,11-trimethyl-5-methylidene-2,3,3a,4,5,6,6a,9,10,10a,13a,14-dodecahydro-1H-cyclopenta[7,8]cyclodeca[1,2-d]isoindole-1,13,15-trione
|
|
CAS | NA | |
PubChem CID | 46209792 | |
ChEMBL ID | CHEMBL1097577 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 528.6 | ALogp: | 3.1 |
HBD: | 4 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 120.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 39 | QED Weighted: | 0.331 |
Caco-2 Permeability: | -5.005 | MDCK Permeability: | 0.00000902 |
Pgp-inhibitor: | 0.04 | Pgp-substrate: | 0.668 |
Human Intestinal Absorption (HIA): | 0.017 | 20% Bioavailability (F20%): | 0.034 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.209 | Plasma Protein Binding (PPB): | 95.83% |
Volume Distribution (VD): | 0.373 | Fu: | 3.85% |
CYP1A2-inhibitor: | 0.049 | CYP1A2-substrate: | 0.51 |
CYP2C19-inhibitor: | 0.547 | CYP2C19-substrate: | 0.681 |
CYP2C9-inhibitor: | 0.411 | CYP2C9-substrate: | 0.137 |
CYP2D6-inhibitor: | 0.116 | CYP2D6-substrate: | 0.15 |
CYP3A4-inhibitor: | 0.951 | CYP3A4-substrate: | 0.428 |
Clearance (CL): | 8.625 | Half-life (T1/2): | 0.097 |
hERG Blockers: | 0.088 | Human Hepatotoxicity (H-HT): | 0.333 |
Drug-inuced Liver Injury (DILI): | 0.293 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.931 | Maximum Recommended Daily Dose: | 0.968 |
Skin Sensitization: | 0.103 | Carcinogencity: | 0.142 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.008 |
Respiratory Toxicity: | 0.985 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004469 | 0.785 | D0W7WC | 0.257 | ||||
ENC002166 | 0.779 | D0S0LZ | 0.255 | ||||
ENC004447 | 0.714 | D0SP3D | 0.249 | ||||
ENC002681 | 0.701 | D09NNH | 0.249 | ||||
ENC002442 | 0.688 | D0V3ZA | 0.249 | ||||
ENC002682 | 0.674 | D01TSI | 0.242 | ||||
ENC002440 | 0.662 | D02DMQ | 0.240 | ||||
ENC002953 | 0.636 | D05EJG | 0.240 | ||||
ENC002443 | 0.577 | D05MQK | 0.239 | ||||
ENC004470 | 0.561 | D09ZIO | 0.236 |